Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  AbbVie    ABBV

ABBVIE (ABBV)
My previous session
Most popular
  Report  
Real-time Quote. Real-time Cboe BZX - 07/23 07:32:25 pm
89.49 USD   +0.65%
07/20ABBVIE : Announces HUMIRA Patent License with Mylan
AQ
07/17ABBVIE : Signs Humira Patent License with Mylan
DJ
07/17ABBVIE : Announces HUMIRA® (adalimumab) Patent License with Mylan
PR
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

Research Results from AbbVie Update Understanding of Medicinal Chemistry (Beyond the Rule of 5: Lessons Learned from AbbVie's Drugs and Compound...

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/05/2017 | 05:58pm CEST

Research Results from AbbVie Update Understanding of Medicinal Chemistry (Beyond the Rule of 5: Lessons Learned from AbbVie's Drugs and Compound Collection)

By a News Reporter-Staff News Editor at Drug Week -- New research on Health and Medicine - Medicinal Chemistry is the subject of a report. According to news reporting originating from North Chicago, Illinois, by NewsRx correspondents, research stated, "Recently, there has been an increasing focus on the pursuit of targets considered to be less druggable that offer potential for development of promising new therapeutic agents for the treatment of diseases with large unmet medical need, particularly in the areas of oncology and virology. However, conducting drug discovery campaigns in 'beyond rule of 5' (bRo5) chemical space presents a significant drug design and development challenge to medicinal chemists to achieve acceptable oral pharmacokinetics."

Our news editors obtained a quote from the research from AbbVie, "Retrospective analysis of past successes and failures in drug discovery bRo5 may shed light on the key principles that contribute to the oral bioavailability of successful bRo5 compounds and improve the efficiency of drug design for future projects. We present here highlights and case studies of lessons learned from discovery of bRo5 compounds."

According to the news editors, the research concluded: "A simple multiparametric scoring function (AB-MPS) was devised that correlated preclinical PK results with cLogD, number of rotatable bonds, and number of aromatic rings."

For more information on this research see: Beyond the Rule of 5: Lessons Learned from AbbVie's Drugs and Compound Collection. Journal of Medicinal Chemistry, 2017;():. (American Chemical Society - www.acs.org; Journal of Medicinal Chemistry - www.pubs.acs.org/journal/jmcmar)

The news editors report that additional information may be obtained by contacting D.A. DeGoey, Research and Development, AbbVie Inc , 1 North Waukegan Road, North Chicago, Illinois 60064, United States. Additional authors for this research include H.J. Chen, P.B. Cox and M.D Wendt (see also Health and Medicine - Medicinal Chemistry).

The direct object identifier (DOI) for that additional information is: https://doi.org/10.1021/acs.jmedchem.7b00717. This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.

Keywords for this news article include: Illinois, North Chicago, United States, Drugs and Therapies, Health and Medicine, Medicinal Chemistry, North and Central America.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC

(c) 2017 NewsRx LLC, source Health Newsletters

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ABBVIE
07/20TODAY’S RESEARCH REPORTS ON STOCKS T : eBay and AbbVie
AC
07/20ABBVIE : Announces HUMIRA Patent License with Mylan
AQ
07/19ABBVIE : Reports from Abbvie Inc. Describe Recent Advances in Chronic Lymphocyti..
AQ
07/19ABBVIE : New Drug Development Findings Has Been Reported by Investigators at Abb..
AQ
07/19ABBVIE : Reports from AbbVie Provide New Insights into Biopharmaceuticals (Predi..
AQ
07/193 Biotech Stocks to Watch This Quarter
AC
07/17ABBVIE : Signs Humira Patent License with Mylan
DJ
07/17ABBVIE : Announces HUMIRA® (adalimumab) Patent License with Mylan
PR
07/16ABBVIE : Announces Submission of Supplemental New Drug Application to US FDA for..
AQ
07/14ABBVIE : Announces Submission Of Supplemental New Drug Application To US FDA For..
AQ
More news
News from SeekingAlpha
07/20QUARTERLY REVIEW OF DIVGRO : Q2 2018 
07/20Citron Protection For AbbVie 
07/19My Dividend Growth Portfolio - Q2 2018 Summary 
07/19Jane's June Dividend Increases And Income - Retirement Accounts 
07/19Big Pharma in the red on ramped up pressure on drug prices 
Financials ($)
Sales 2018 32 950 M
EBIT 2018 14 435 M
Net income 2018 10 789 M
Debt 2018 29 248 M
Yield 2018 4,06%
P/E ratio 2018 12,87
P/E ratio 2019 11,48
EV / Sales 2018 5,17x
EV / Sales 2019 4,78x
Capitalization 141 B
Chart ABBVIE
Duration : Period :
AbbVie Technical Analysis Chart | 4-Traders
Full-screen chart
Technical analysis trends ABBVIE
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 113 $
Spread / Average Target 27%
EPS Revisions
Managers
NameTitle
Richard A. Gonzalez Chairman & Chief Executive Officer
Azita Saleki-Gerhardt Senior Vice President-Operations
William J. Chase Chief Financial Officer & Executive Vice President
Michael E. Severino Chief Scientific Officer & Executive VP
Robert J. Alpern Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
ABBVIE-8.07%142 740
MERCK KGAA-4.36%13 006
KYOWA HAKKO KIRIN CO LTD-2.57%11 111
ZHANGZHOU PIENTZEHUANG PHARMACEUTICL LTD93.01%10 926
JAZZ PHARMACEUTICALS PLC31.07%10 677
CONVATEC GROUP-0.24%5 232